Hims & Hers Announces Planned 2026 Expansion to Canada, Following ZAVA Acquisition Completion

About this update from Hims & Hers Health, Inc.

[{"type":"image","alt":"The company's entry to Canada will come as generic semaglutide hits the market for the first time, marking a major step in expanding access to affordable weight loss care.","displaySize":"","headline":null,"caption":"The company's entry to Canada will come as generic semaglutide hits the market for the first time, marking a major step in expanding access to affordable weight loss care.","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":325,"url":"https://media.zenfs.com/en/business-wire.com/6fcb3dc7d5db060211adce80eec5c10a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MLqC8lCmBwkhH0Oq5zNIAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY1MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6fcb3dc7d5db060211adce80eec5c10a","width":480,"height":325}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2562,"height":408,"url":"https://media.zenfs.com/en/business-wire.com/7761b4a829125d86b4ede0fb3f12110c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BfdGEgZDeddBo7xBBo7RBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE1MztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7761b4a829125d86b4ede0fb3f12110c","width":960,"height":153},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/K57Apsr5OuG9j3gxmzSIGg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zODI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/7761b4a829125d86b4ede0fb3f12110c","width":1200,"height":191}}},{"type":"text","content":"Entry to Canada will come as generic semaglutide hits the market for the first time, marking a major step in expanding access to affordable weight loss care","length":156,"tagName":"p","attribs":{}},{"type":"text","content":"SAN FRANCISCO, July 09, 2025--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) the leading digital health and wellness platform, today announced its plans to bring its affordable, holistic weight loss program to Canada, timed with the anticipated first-ever availability of generic semaglutide anywhere in the world. This move follows the recent closing of the company's acquisition of ZAVA, the pioneering digital health platform in Europe.","length":455,"tagName":"p"},{"type":"text","content":"Almost two thirds of adults in Canada are overweigh...

More updates from Hims & Hers Health, Inc.